Professor Riste?rd ? Laoide:

The bandwidth between the survival figures is not enormous. There is around 10% difference between the best and the worst, with Sweden being the best. The reason for that is that we need to centralise. We are working on centralising ovarian cancer services, particularly high-end ovarian cancer services. I guess the figures we have are from around 2014 to 2018. There have been significant improvements since then.